Obesity medication lorcaserin activates brainstem GLP-1 neurons to reduce food intake and augments GLP-1 receptor agonist induced appetite suppression.

ABSTRACT:

Objective

Overweight and obesity are endemic in developed countries, with a substantial negative impact on human health. Medications developed to treat obesity include agonists for the G-protein coupled receptors glucagon-like peptide-1 (GLP-1R; e.g. liraglutide), serotonin 2C (5-HT_2CR; e.g, lorcaserin), and melanocortin4 (MC4R) which reduce body weight primarily by suppressing food intake. However, the mechanisms underlying the therapeutic food intake suppressive effects are still being defined and were investigated here.

Methods

We profiled PPG neurons in the nucleus of the solitary tract (PPG^NTS) using single nucleus RNA sequencing (Nuc-Seq) and histochemistry. We next examined the requirement of PPG^NTS neurons for obesity medication effec

SUBMITTER: Wagner S 

PROVIDER: S-EPMC9841057 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature